Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension

Pulmonary arterial hypertension (PAH) is a life-threatening disease that can be induced by dasatinib, a dual Src and BCR-ABL tyrosine kinase inhibitor that is used to treat chronic myelogenous leukemia (CML). Today, key questions remain regarding the mechanisms involved in the long-term development...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Invest
Autores principales: Guignabert, Christophe, Phan, Carole, Seferian, Andrei, Huertas, Alice, Tu, Ly, Thuillet, Raphaël, Sattler, Caroline, Le Hiress, Morane, Tamura, Yuichi, Jutant, Etienne-Marie, Chaumais, Marie-Camille, Bouchet, Stéphane, Manéglier, Benjamin, Molimard, Mathieu, Rousselot, Philippe, Sitbon, Olivier, Simonneau, Gérald, Montani, David, Humbert, Marc
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2016
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5004960/
https://ncbi.nlm.nih.gov/pubmed/27482885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI86249
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares